Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Evolution - 3rd phase

<< Previous

Bullboard Posts

Next >>

Comment by Chianchinon Apr 11, 2021 8:41pm

80 Views

Post# 32975332

RE:RE:RE:Evolution - 3rd phase

All of the "intelligent" decision GUD made in the past six Years has resulted for the share price down by 50%. No investors, unless mad, buys a private placement to be down 50% six Years later and be happy. Reward means share price higher than the PP. I am shocked you do not know! Playing dumb ha..? The only investment sector happy with GUD intelligent performance has been short sellers. A no brainer. Another alias name but same person reaperance.

<< Previous

Bullboard Posts

Next >>

Three micro-cap value stocks trading at peak pessimism